Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Date:2/10/2011

ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2010.

"2010 has been an exceptional milestone year in the history of our company.  Our first product, Fanapt®, reached the U.S. market for the treatment of schizophrenia, we had our first profitable year and we have advanced our second asset, tasimelteon, in Phase 3 studies," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer. "2011 will be a foundation year for Vanda, as we begin to execute upon our vision of building a world class neuroscience pharmaceutical company."

Key Highlights:

  • Vanda recorded 2010 revenue of $35.2 million including royalties and product sales of $8.4 million.  
  • Cash and cash equivalents plus marketable securities at year end 2010 were $198.0 million as compared to $205.3 million at year end 2009.
  • Monthly prescriptions of Fanapt®, as reported by IMS, increased from over 6,000 in September of 2010 to over 8,000 in December of 2010. For the full year 2010, more than 55,000 prescriptions have been written.
  • Tasimelteon efficacy and safety studies are ongoing in both the U.S. and Europe.
  • On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal Revenue Service (IRS) clarifying the company's ability to utilize net operating loss carryforwards for tax purposes.  

  • Full Year 2010 Reported ResultsTotal revenues for the full year 2010 were $35.2 million, compared to $4.5 million for the same period in 2009.  2010 revenues included $26.8 million recognized from the $2
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
    4. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
    6. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
    7. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
    9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
    10. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
    11. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
    (Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
    (Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
    (Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
    Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
    ... The J. R. Simplot Company,s Plant Sciences ... for improving crops, leading to new, better and ...   Innate™ Technology is a patented ... own genes to enhance desirable traits and to ...
    ... SUNNYVALE, Calif., July 12, 2011 Molecular Devices ... discovery & development, life science research, and bioassay/test ... functionality of the SoftMax® Pro Software and prominence ... control ability via an Apple iPad wireless device. ...
    ... New research from the Trudeau Institute may help to ... lives of patients with sepsis. The study was led by ... shows that fibrin, a key product of the blood clotting ... , a gram-negative bacterium that causes sepsis in humans and ...
    Cached Biology Technology:Molecular Devices Enables Intuitive Functionality at Your Fingertips on the Apple iPad with the Latest SoftMax Pro Software 2Trudeau Institute announces a discovery in the fight against sepsis 2
    (Date:4/20/2014)... Most drugs used to treat lung, breast and pancreatic ... Researchers at the University of California, San Diego School ... CD61 on the surface of drug-resistant tumors that appears ... cell-like properties of cancer cells. , The findings, ... Nature Cell Biology , may point to new ...
    (Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
    (Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
    Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
    ... Hormone replacement therapies, or medications containing female hormones ... body, are often prescribed to reduce the effects ... women. Research and clinical trials on hormone replacement ... especially breast cancer, in post-menopausal women who take ...
    ... been elected as a fellow of the American ... organization,s Council on Basic Cardiovascular Sciences., Nguyen, who ... 2005, specializes in cellular engineering. Her research also ... therapies., Liping Tang, interim chairman of the UT ...
    ... Houser, PhD, FAHA, Director of the Cardiovascular Research Center ... studying the heart for nearly three and a half ... to cardiovascular research, work that led to his recent ... Association (AHA) the Basic Cardiovascular Science (BCVS) Council ...
    Cached Biology News:Women prescribed combination HRT should use caution when taking apigenin supplement, MU study finds 2Temple's Dr. Steven Houser recognized by the American Heart Association 2Temple's Dr. Steven Houser recognized by the American Heart Association 3
    Polio component type I...
    Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
    ... comprehensive microarray service for systematic discovery ... non-coding RNAs (ncRNAs) using a novel ... which enables highly sensitive and specific ... This comprehensive service includes custom probe ...
    ... LC Sciences provides a comprehensive ... protein kinase substrate (PKS) peptide microarrays ... proteomic scale kinase profiling, quantitative measurement ... discovery research. This comprehensive service includes ...
    Biology Products: